Serhat Güler1, Gözde Yeşil2, Hasan Önal3. 1. Clinic of Pediatric Neurology, Edirne Sultan 1st Murat State Hospital, Edirne, Turkey. 2. Department of Medical Genetics, Bezmialem Vakıf University School of Medicine, İstanbul, Turkey. 3. Clinic of Pediatric Endocrinology and Metabolic Diseases, Kanuni Sultan Süleyman Training and Research Hospital, İstanbul, Turkey.
Abstract
BACKGROUND: Neurofibromatosis type 1 is an autosomal dominant neurocutaneous disorder in which the coexistence of autoimmune thyroiditis and thyroid gland tumours has been reported previously. AIMS: To determine the thyroid function and autoimmune thyroid diseases in neurofibromatosis type 1 patients in order to identify the possible association between neurofibromatosis type 1 and thyroid diseases. STUDY DESIGN: Case-control study. METHODS: The study includes 78 consecutive patients diagnosed with neurofibromatosis type 1 between June 2010 and June 2014 and 50 healthy controls. Baseline demographic data were generated from patient examination record forms, including age, sex, height, and weight, as well as levels of free triiodothyronine, free thyroxine, thyroid-stimulating hormone, anti-thyroid peroxidase and anti-thyroglobulin levels. RESULTS: Mean age, sex, and body mass index were similar in both groups (p>0.05). The mean levels of free triiodothyronine, free thyroxine, and thyroid-stimulating hormone were not statistically different between the neurofibromatosis type 1 and control groups. Similarly, no statistically significant difference was observed between the neurofibromatosis type 1 and control groups for anti-thyroid peroxidase and anti-thyroglobulin positivity (2.5% vs 0%, p>0.05). CONCLUSION: Screening for autoimmune thyroid disease and thyroid function seems to be unnecessary in patients with neurofibromatosis type 1.
BACKGROUND:Neurofibromatosis type 1 is an autosomal dominant neurocutaneous disorder in which the coexistence of autoimmune thyroiditis and thyroid gland tumours has been reported previously. AIMS: To determine the thyroid function and autoimmune thyroid diseases in neurofibromatosis type 1patients in order to identify the possible association between neurofibromatosis type 1 and thyroid diseases. STUDY DESIGN: Case-control study. METHODS: The study includes 78 consecutive patients diagnosed with neurofibromatosis type 1 between June 2010 and June 2014 and 50 healthy controls. Baseline demographic data were generated from patient examination record forms, including age, sex, height, and weight, as well as levels of free triiodothyronine, free thyroxine, thyroid-stimulating hormone, anti-thyroid peroxidase and anti-thyroglobulin levels. RESULTS: Mean age, sex, and body mass index were similar in both groups (p>0.05). The mean levels of free triiodothyronine, free thyroxine, and thyroid-stimulating hormone were not statistically different between the neurofibromatosis type 1 and control groups. Similarly, no statistically significant difference was observed between the neurofibromatosis type 1 and control groups for anti-thyroid peroxidase and anti-thyroglobulin positivity (2.5% vs 0%, p>0.05). CONCLUSION: Screening for autoimmune thyroid disease and thyroid function seems to be unnecessary in patients with neurofibromatosis type 1.
Authors: D Viskochil; A M Buchberg; G Xu; R M Cawthon; J Stevens; R K Wolff; M Culver; J C Carey; N G Copeland; N A Jenkins Journal: Cell Date: 1990-07-13 Impact factor: 41.582
Authors: Antonio Ciardi; Giorgio Trombetta; Lorenzo Memeo; Angeloluca De Quarto; Ugo Di Tondo Journal: Pathol Oncol Res Date: 1997 Impact factor: 3.201
Authors: Elizabeth A Soucy; Dorothy van Oppen; Nicole L Nejedly; Feng Gao; David H Gutmann; Abby S Hollander Journal: J Child Neurol Date: 2012-06-29 Impact factor: 1.987
Authors: R Virdis; M E Street; M A Bandello; C Tripodi; A Donadio; A R Villani; L Cagozzi; L Garavelli; S Bernasconi Journal: J Pediatr Endocrinol Metab Date: 2003-03 Impact factor: 1.634
Authors: David A Ingram; Lei Zhang; Jennifer McCarthy; Mary Jo Wenning; Lucy Fisher; Feng-Chun Yang; D Wade Clapp; Reuben Kapur Journal: Blood Date: 2002-07-05 Impact factor: 22.113